Found: 95
Select item for more details and to access through your institution.
Effect of concurrent beta-blocker use in patients receiving immune checkpoint inhibitors for advanced solid tumors.
- Published in:
- Journal of Cancer Research & Clinical Oncology, 2023, v. 149, n. 7, p. 2833, doi. 10.1007/s00432-022-04159-y
- By:
- Publication type:
- Article
Cabazitaxel.
- Published in:
- 2010
- By:
- Publication type:
- journal article
Geographic Accessibility to Clinical Trials for Advanced Cancer in the United States.
- Published in:
- JAMA Internal Medicine, 2015, v. 175, n. 2, p. 293, doi. 10.1001/jamainternmed.2014.6300
- By:
- Publication type:
- Article
Ability of C-reactive protein to complement multiple prognostic classifiers in men with metastatic castration resistant prostate cancer receiving docetaxel-based chemotherapy.
- Published in:
- BJU International, 2012, v. 110, n. 11b, p. E461, doi. 10.1111/j.1464-410X.2012.11148.x
- By:
- Publication type:
- Article
Targeting the androgen receptor signalling axis in castration-resistant prostate cancer (CRPC).
- Published in:
- BJU International, 2012, v. 110, n. 11, p. 1580, doi. 10.1111/j.1464-410X.2012.11445.x
- By:
- Publication type:
- Article
Novel agents for muscle-invasive and advanced urothelial cancer.
- Published in:
- BJU International, 2008, v. 101, n. 8, p. 937, doi. 10.1111/j.1464-410X.2007.07326.x
- By:
- Publication type:
- Article
Concurrent diabetes mellitus may negatively influence clinical progression and response to androgen deprivation therapy in patients with advanced prostate cancer.
- Published in:
- Frontiers in Oncology, 2015, p. 1, doi. 10.3389/fonc.2015.00129
- By:
- Publication type:
- Article
Collaborative study from the Bladder Cancer Advocacy Network for the genomic analysis of metastatic urothelial cancer.
- Published in:
- Nature Communications, 2022, v. 13, n. 1, p. 1, doi. 10.1038/s41467-022-33980-9
- By:
- Publication type:
- Article
Adjuvant nivolumab versus placebo following radical surgery for high-risk muscle-invasive urothelial carcinoma: a subgroup analysis of Japanese patients enrolled in the phase 3 CheckMate 274 trial.
- Published in:
- Japanese Journal of Clinical Oncology, 2023, v. 53, n. 1, p. 16, doi. 10.1093/jjco/hyac155
- By:
- Publication type:
- Article
A SEER-Medicare Based Quality Score for Patients With Metastatic Upper Tract Urothelial Carcinoma.
- Published in:
- Clinical Genitourinary Cancer, 2024, v. 22, n. 1, p. 14, doi. 10.1016/j.clgc.2023.06.010
- By:
- Publication type:
- Article
Metastasis Within Three Years from Radical Nephroureterectomy as a Potential Surrogate for Overall Survival.
- Published in:
- Clinical Genitourinary Cancer, 2022, v. 20, n. 4, p. 389.e1, doi. 10.1016/j.clgc.2022.03.007
- By:
- Publication type:
- Article
Characterizing Prostate-Specific Antigen Levels at Death in Patients with Metastatic Castration-Resistant Prostate Cancer: Are We Underutilizing Imaging?
- Published in:
- Clinical Genitourinary Cancer, 2021, v. 19, n. 6, p. e346, doi. 10.1016/j.clgc.2021.04.003
- By:
- Publication type:
- Article
Pan-cancer proteogenomic investigations identify post-transcriptional kinase targets.
- Published in:
- Communications Biology, 2021, v. 4, n. 1, p. 1, doi. 10.1038/s42003-021-02636-7
- By:
- Publication type:
- Article
A first-in-human phase I study of TAS0728, an oral covalent binding inhibitor of HER2, in patients with advanced solid tumors with HER2 or HER3 aberrations.
- Published in:
- Investigational New Drugs, 2021, v. 39, n. 5, p. 1324, doi. 10.1007/s10637-021-01104-7
- By:
- Publication type:
- Article
Nivolumab in patients with unresectable locally advanced or metastatic urothelial carcinoma: CheckMate 275 2-year global and Japanese patient population analyses.
- Published in:
- International Journal of Clinical Oncology, 2019, v. 24, n. 9, p. 1089, doi. 10.1007/s10147-019-01450-w
- By:
- Publication type:
- Article
TO PUT THAT INTO CONTEXT.
- Published in:
- Oncology (08909091), 2016, v. 30, n. 6, p. 575
- By:
- Publication type:
- Article
SIU-ICUD recommendations on bladder cancer: systemic therapy for metastatic bladder cancer.
- Published in:
- World Journal of Urology, 2019, v. 37, n. 1, p. 95, doi. 10.1007/s00345-018-2486-1
- By:
- Publication type:
- Article
Immune phenotype of peripheral blood mononuclear cells in patients with high-risk non-muscle invasive bladder cancer.
- Published in:
- World Journal of Urology, 2018, v. 36, n. 11, p. 1741, doi. 10.1007/s00345-018-2359-7
- By:
- Publication type:
- Article
Cytoreductive nephrectomy for metastatic renal cell carcinoma in the era of targeted therapy in the United States: a SEER analysis.
- Published in:
- World Journal of Urology, 2013, v. 31, n. 6, p. 1535, doi. 10.1007/s00345-012-1001-3
- By:
- Publication type:
- Article
Incidence of hepatotoxicity associated with addition of immune checkpoint blockade to systemic solid tumor therapy: a meta-analysis of phase 3 randomized controlled trials.
- Published in:
- Cancer Immunology, Immunotherapy, 2022, v. 71, n. 12, p. 2837, doi. 10.1007/s00262-022-03203-7
- By:
- Publication type:
- Article
Early Mortality in Patients With Muscle-Invasive Bladder Cancer Undergoing Cystectomy in the United States.
- Published in:
- JNCI Cancer Spectrum, 2018, v. 2, n. 4, p. N.PAG, doi. 10.1093/jncics/pky075
- By:
- Publication type:
- Article
Metabolic disease and adverse events from immune checkpoint inhibitors.
- Published in:
- European Journal of Endocrinology, 2021, v. 184, n. 6, p. 857, doi. 10.1530/EJE-20-1362
- By:
- Publication type:
- Article
Phase II trial of pemetrexed as second-line therapy in patients with metastatic urothelial carcinoma.
- Published in:
- Investigational New Drugs, 2007, v. 25, n. 3, p. 265, doi. 10.1007/s10637-006-9020-9
- By:
- Publication type:
- Article
Phase 1b study to assess the safety, tolerability, and clinical activity of pamiparib in combination with temozolomide in patients with locally advanced or metastatic solid tumors.
- Published in:
- Cancer Medicine, 2024, v. 13, n. 13, p. 1, doi. 10.1002/cam4.7385
- By:
- Publication type:
- Article
Venous thromboembolism in metastatic urothelial carcinoma or variant histologies: incidence, associative factors, and effect on survival.
- Published in:
- Cancer Medicine, 2017, v. 6, n. 1, p. 186, doi. 10.1002/cam4.986
- By:
- Publication type:
- Article
The Evolving Clinical Management of Genitourinary Cancers Amid the COVID-19 Pandemic.
- Published in:
- Frontiers in Oncology, 2021, v. 11, p. 1, doi. 10.3389/fonc.2021.734963
- By:
- Publication type:
- Article
Moving beyond vascular endothelial growth factor-targeted therapy in renal cell cancer: latest evidence and therapeutic implications.
- Published in:
- Therapeutic Advances in Medical Oncology, 2017, v. 9, n. 4, p. 287, doi. 10.1177/1758834016687261
- By:
- Publication type:
- Article
Precision Medicine in Urothelial Carcinoma: Current Markers to Guide Treatment and Promising Future Directions.
- Published in:
- Current Treatment Options in Oncology, 2023, v. 24, n. 12, p. 1870, doi. 10.1007/s11864-023-01151-7
- By:
- Publication type:
- Article
Neoadjuvant Therapy Followed by Prostatectomy for Clinically Localized Prostate Cancer.
- Published in:
- Cancer (0008543X), 2007, v. 110, n. 12, p. 2628, doi. 10.1002/cncr.23085
- By:
- Publication type:
- Article
Phase II trial of dose‐dense doxorubicin plus gemcitabine followed by paclitaxel plus carboplatin in patients with advanced urothelial carcinoma and impaired renal functionPresented in part at the American Society of Clinical Oncology 2005 Annual Meeting.
- Published in:
- Cancer (0008543X), 2007, v. 109, n. 3, p. 549, doi. 10.1002/cncr.22454
- By:
- Publication type:
- Article
Impact of renal impairment on eligibility for adjuvant cisplatin‐based chemotherapy in patients with urothelial carcinoma of the bladder.
- Published in:
- Cancer (0008543X), 2006, v. 107, n. 3, p. 506
- By:
- Publication type:
- Article
A retrospective evaluation of second‐line chemotherapy response in hormone‐refractory prostate carcinoma: Second‐line taxane‐based therapy after first‐line epothilone‐B analog ixabepilone (BMS‐247550) therapy
- Published in:
- Cancer (0008543X), 2006, v. 106, n. 1, p. 58, doi. 10.1002/cncr.21559
- By:
- Publication type:
- Article
All roads lead to PP2A: exploiting the therapeutic potential of this phosphatase.
- Published in:
- FEBS Journal, 2016, v. 283, n. 6, p. 1004, doi. 10.1111/febs.13573
- By:
- Publication type:
- Article
ARID1A mutation plus CXCL13 expression act as combinatorial biomarkers to predict responses to immune checkpoint therapy in mUCC.
- Published in:
- Science Translational Medicine, 2020, v. 12, n. 548, p. 1, doi. 10.1126/scitranslmed.abc4220
- By:
- Publication type:
- Article
Benchmarking Maintenance Therapy Survival in First-Line Platinum-Based Chemotherapy–Treated Patients with Advanced Urothelial Carcinoma Using Simulated Disease Modeling.
- Published in:
- Clinical Epidemiology, 2023, v. 15, p. 765, doi. 10.2147/CLEP.S409791
- By:
- Publication type:
- Article
Oncology Simulation Model: A Comprehensive and Innovative Approach to Estimate and Project Prevalence and Survival in Oncology.
- Published in:
- Clinical Epidemiology, 2022, v. 14, p. 1375, doi. 10.2147/CLEP.S377093
- By:
- Publication type:
- Article
Survival of Patients with Stage IV Lung Cancer with Diabetes Treated with Metformin.
- Published in:
- American Journal of Respiratory & Critical Care Medicine, 2015, v. 191, n. 4, p. 448, doi. 10.1164/rccm.201407-1395OC
- By:
- Publication type:
- Article
Elevated circulating tissue inhibitor of metalloproteinase 1 (TIMP-1) levels are associated with neuroendocrine differentiation in castration resistant prostate cancer.
- Published in:
- Prostate, 2015, v. 75, n. 6, p. 616, doi. 10.1002/pros.22945
- By:
- Publication type:
- Article
Phase 2 trial of the topoisomerase II inhibitor, amrubicin, as second-line therapy in patients with metastatic urothelial carcinoma.
- Published in:
- 2015
- By:
- Publication type:
- journal article
Heterogeneity in Methods of Estimating Kidney Function for Cancer Clinical Trial Eligibility.
- Published in:
- JAMA Network Open, 2024, v. 7, n. 9, p. e2433387, doi. 10.1001/jamanetworkopen.2024.33387
- By:
- Publication type:
- Article
The natural history of untreated muscle‐invasive bladder cancer.
- Published in:
- BJU International, 2020, v. 125, n. 2, p. 270, doi. 10.1111/bju.14872
- By:
- Publication type:
- Article
Pathological downstaging as a novel endpoint for the development of neoadjuvant chemotherapy for upper tract urothelial carcinoma.
- Published in:
- BJU International, 2019, v. 124, n. 4, p. 665, doi. 10.1111/bju.14719
- By:
- Publication type:
- Article
Chemotherapy regimen is associated with venous thromboembolism risk in patients with urothelial tract cancer.
- Published in:
- BJU International, 2019, v. 124, n. 2, p. 290, doi. 10.1111/bju.14685
- By:
- Publication type:
- Article
Cytotoxic chemotherapy in the contemporary management of metastatic castration-resistant prostate cancer ( mCRPC).
- Published in:
- BJU International, 2015, v. 116, n. 1, p. 17, doi. 10.1111/bju.12867
- By:
- Publication type:
- Article
Cytotoxic chemotherapy in the contemporary management of metastatic castration-resistant prostate cancer (mCRPC).
- Published in:
- BJU International, 2015, v. 115, n. 7, p. 17, doi. 10.1111/bju.12867
- By:
- Publication type:
- Article
Radiographic progression by Prostate Cancer Working Group ( PCWG)-2 criteria as an intermediate endpoint for drug development in metastatic castration-resistant prostate cancer.
- Published in:
- BJU International, 2014, v. 114, n. 6b, p. E25, doi. 10.1111/bju.12589
- By:
- Publication type:
- Article
A nomogram including baseline prognostic factors to estimate the activity of second-line therapy for advanced urothelial carcinoma.
- Published in:
- BJU International, 2014, v. 113, n. 5b, p. E137, doi. 10.1111/bju.12564
- By:
- Publication type:
- Article
Neoadjuvant vs. Adjuvant Chemotherapy in Muscle Invasive Bladder Cancer (MIBC): Analysis From the RISC Database.
- Published in:
- Frontiers in Oncology, 2018, p. N.PAG, doi. 10.3389/fonc.2018.00463
- By:
- Publication type:
- Article
Clinical Development of Cabazitaxel for the Treatment of Castration-Resistant Prostate Cancer.
- Published in:
- Clinical Medicine Insights: Oncology, 2011, n. 5, p. 163, doi. 10.4137/CMO.S6566
- By:
- Publication type:
- Article
Association Between FDA Label Restriction and Immunotherapy and Chemotherapy Use in Bladder Cancer.
- Published in:
- 2019
- By:
- Publication type:
- journal article